SXTPW · 60 Degrees Pharmaceuticals, Inc. · Documents
$0.03
+0.00 (+0.00%)
At close · Oct 26
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Management has evaluated these conditions and its plans to mitigate them and concluded that, collectively, such plans do not alleviate the substantial doubt about the Company's ability to continue as a going concern for at least one year after the date these consolidated condensed financial statements are issued.”View the 10-Q filed Aug 14, 2026
Market Cap
$2.93M
Shares
3.52M
Volume · Oct 26
101
Avg daily vol (3M)
5456
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | AI summary | Filing Date | Period | Open |
|---|---|---|---|---|
| 8-K | 60 Degrees reported clinical improvement and negative conventional PCR results in all five completed expanded access Babesiosis study patients; four were also negative on post-treatment NAT, while two additional patients remain on treatment, bringing enrollment to seven. | 2026-10-27 | — | |
| 8-K | 60 Degrees Pharmaceuticals reports ARAKODA® (tafenoquine) in the US market, ZAMVIO (tafenoquine) for tick-borne disease veterinary indications, and pipeline programs for human babesiosis and PTLD; an interim analysis is dated 10/6/2026, with planning for 2027. | 2026-10-23 | — | |
| 8-K | 60 Degrees Pharmaceuticals will conclude enrollment at 30 subjects in its tafenoquine severe babesiosis study, unblind and report primary and secondary endpoint results in January 2027, and request an FDA pre-sNDA meeting that month; no safety issues were identified. | 2026-10-06 | — | |
| 8-K | — | 2026-09-14 | 2026-09-12 | |
| 8-K | — | 2026-09-08 | — | |
| S-3 | — | 2026-08-14 | — | |
| 10-Q | — | 2026-08-14 | 2026-06-30 | |
| 8-K | — | 2026-08-06 | 2026-08-05 | |
| 8-K | — | 2026-08-04 | 2026-07-30 | |
| 8-K | — | 2026-07-20 | — | |
| 8-K | — | 2026-07-09 | 2026-07-07 | |
| DEF 14A | — | 2026-07-02 | 2026-08-05 | |
| PRE 14A | — | 2026-06-08 | — | |
| 8-K | — | 2026-06-03 | — | |
| 8-K | — | 2026-05-18 | 2026-05-13 | |
| 10-Q | — | 2026-05-15 | 2026-03-31 | |
| 10-K | — | 2026-03-30 | 2025-12-31 | |
| 8-K | — | 2026-03-20 | — | |
| 8-K | — | 2026-03-13 | — | |
| 8-K | — | 2026-03-12 | — | |
| 8-K | — | 2026-02-12 | 2026-02-11 | |
| 8-K | — | 2026-01-23 | 2026-01-20 | |
| 8-K | — | 2026-01-21 | 2026-01-14 | |
| 8-K | — | 2026-01-08 | — | |
| 10-Q | — | 2025-11-13 | 2025-09-30 | |
| 8-K | — | 2025-10-10 | 2025-10-08 | |
| 8-K | — | 2025-09-09 | — | |
| 8-K | — | 2025-09-05 | 2025-09-03 | |
| DEFR14A | — | 2025-09-02 | — | |
| DEF 14A | — | 2025-08-27 | 2025-10-08 | |
| PRE 14A | — | 2025-08-15 | — | |
| 10-Q | — | 2025-08-13 | 2025-06-30 | |
| 8-K | — | 2025-07-18 | 2025-07-15 | |
| S-1 | — | 2025-07-07 | — | |
| 10-Q | — | 2025-05-15 | 2025-03-31 | |
| 8-K | — | 2025-04-09 | 2025-04-04 | |
| 10-K | — | 2025-03-27 | 2024-12-31 | |
| S-1/A | — | 2025-03-27 | — | |
| S-1 | — | 2025-02-14 | — | |
| 8-K | — | 2025-02-06 | 2025-02-05 | |
| 8-K | — | 2025-01-30 | 2025-01-28 | |
| 8-K | — | 2025-01-28 | — | |
| 8-K | — | 2025-01-08 | — | |
| 10-Q | — | 2024-11-14 | 2024-09-30 | |
| 8-K | — | 2024-11-06 | — | |
| DEF 14A | — | 2024-10-15 | 2024-11-06 | |
| 8-K | — | 2024-10-08 | 2024-10-02 | |
| PRE 14A | — | 2024-10-02 | — | |
| S-3 | — | 2024-09-19 | — | |
| 8-K | — | 2024-09-06 | 2024-09-04 |
Showing 1–50 of 85 filings